|
|
|
Volumn 2, Issue 5, 1999, Pages 400-402
|
|
Innovation in cardiovascular drugs: Drug development portfolios: 3-4 March 1999, London, UK
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADENOSINE RECEPTOR STIMULATING AGENT;
ANGIOTENSIN;
ANTIASTHMATIC AGENT;
ANTILIPEMIC AGENT;
ANTIRHEUMATIC AGENT;
ARGATROBAN;
BIMOSIAMOSE;
CARDIOVASCULAR AGENT;
CARVEDILOL;
ENDOTHELIN A RECEPTOR ANTAGONIST;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LEX 032;
MATRIX METALLOPROTEINASE INHIBITOR;
RANOLAZINE;
RECOMBINANT PROTEIN;
SITAXSENTAN;
TBC 3486;
TECADENOSON;
UNCLASSIFIED DRUG;
VACCINE;
ACUTE HEART INFARCTION;
ANIMAL MODEL;
ANTICOAGULANT THERAPY;
ASTHMA;
ATHEROSCLEROSIS;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
CONFERENCE PAPER;
CORONARY ARTERY DISEASE;
GENE THERAPY;
HEART ARRHYTHMIA;
HEART FAILURE;
HUMAN;
HYPERTENSION;
NONHUMAN;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
RAT;
RHEUMATOID ARTHRITIS;
UNSTABLE ANGINA PECTORIS;
VACCINATION;
|
|
EID: 0032920505
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (1)
|
|
References (0)
|
